aid: epizyme
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/epizyme.png
name: Epizyme
description: 'Epizyme, Inc. was a Cambridge, Massachusetts biopharmaceutical company
  developing epigenetic therapies for cancer and other diseases. Its lead product,
  TAZVERIK (tazemetostat), is an oral EZH2 inhibitor approved by the FDA for epithelioid
  sarcoma and relapsed/refractory follicular lymphoma. Epizyme was acquired by Ipsen
  in 2022. It was added to the API Evangelist network as a stub via the kleiner-perkins
  venture portfolio; the company operates no public developer program, API, or
  documentation surface, and its former corporate website (epizyme.com) is no longer
  serving a web presence though the domain remains registered and mail-active.'
url: https://raw.githubusercontent.com/api-evangelist/epizyme/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- kleiner-perkins
x-tier: stub
x-tier-reason: portfolio-lead
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Healthcare
- Biotechnology
- Pharmaceuticals
- Oncology
- Epigenetics
apis: []
common:
- type: Website
  url: https://www.epizyme.com
- type: DomainSecurity
  url: security/epizyme-domain-security.yml
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence